Utilizar o estilo visual didático característico de Stahl para explicar mecanismos de sinalização de neurotransmissores. Stahl's Essential Psychopharmacology - Amazon.com
A 5ª edição do livro "Psicofarmacologia" de Stephen M. Stahl inclui os seguintes tópicos: psicofarmacologia stahl 5 edi%C3%A7%C3%A3o pdf gr%C3%A1tis
: This is the official comprehensive resource for Dr. Stephen M. Stahl's works, including the latest editions and the Prescriber's Guide . Utilizar o estilo visual didático característico de Stahl
The treatment of MDD, one of the most prevalent psychiatric disorders, has seen significant advancements. The monoamine hypothesis, which posits that depression is related to deficiencies in serotonin, norepinephrine, and dopamine, remains a cornerstone of antidepressant therapy. However, newer agents, such as vortioxetine and vilazodone, have expanded our understanding of the role of multiple neurotransmitter systems in MDD treatment. Stephen M
| Chapter | Drug Class | Notable Updates in 5th ed. | |---------|------------|---------------------------| | 5 | | Re‑emphasis on when to consider TCAs in treatment‑resistant depression; safety checklist for MAOIs. | | 6 | SSRIs & SNRIs | New data on escitalopram, duloxetine, venlafaxine XR; discussion of sexual dysfunction mitigation strategies. | | 7 | Atypical Antidepressants (Bupropion, Mirtazapine, Vortioxetine) | Vortioxetine’s multimodal action & cognitive benefits. | | 8 | Mood Stabilizers – Lithium | Updated lithium‑nephrotoxicity monitoring protocol; pharmacogenomic considerations. | | 9 | Anticonvulsant Mood Stabilizers | Lamotrigine, valproate, carbamazepine, topiramate – comparative efficacy tables for bipolar I/II. | |10 | First‑Generation Antipsychotics | Revised EPS risk calculator; focus on long‑acting injectable (LAI) formulations. | |11 | Second‑Generation Antipsychotics | New agents (brexpiprazole, cariprazine) and deeper discussion on metabolic risk mitigation. | |12 | Third‑Generation/Partial Agonists | Mechanistic deep dive into aripiprazole, cariprazine, brexpiprazole – functional selectivity explained. | |13 | Anxiolytics – Benzodiazepines | Updated safety profile, dependence risk, and tapering algorithms. | |14 | Non‑benzodiazepine Anxiolytics (Buspirone, Hydroxyzine) | Clinical decision tree for anxiety subtypes. | |15 | Stimulants & Non‑stimulant ADHD Meds | New data on lisdexamfetamine, guanfacine XR, and viloxazine. | |16 | Sedative‑hypnotics | Review of zolpidem, eszopiclone, and emerging orexin antagonists (suvorexant). | |17 | Cognitive Enhancers & Alzheimer’s Agents | Donepezil, rivastigmine, memantine, and investigational agents (e.g., aducanumab) – brief neuro‑ethical commentary. | |18 | Substance‑Use Disorder Pharmacotherapies | Naltrexone, acamprosate, disulfiram, buprenorphine, and extended‑release formulations. |
inspiracije